Frontiers in Oncology (Mar 2022)

EPHX2 Inhibits Colon Cancer Progression by Promoting Fatty Acid Degradation

  • Yiran Zhou,
  • Yiran Zhou,
  • Xiao Li,
  • Xiao Li,
  • Aoran Guan,
  • Aoran Guan,
  • Haodong Zhou,
  • Haodong Zhou,
  • Yankun Zhu,
  • Yankun Zhu,
  • Ruotian Wang,
  • Ruotian Wang,
  • Ruhong Li,
  • Ruhong Li

DOI
https://doi.org/10.3389/fonc.2022.870721
Journal volume & issue
Vol. 12

Abstract

Read online

Tumor cells use metabolic reprogramming to keep up with the need for bioenergy, biosynthesis, and oxidation balance needed for rapid tumor division. This phenomenon is considered a marker of tumors, including colon cancer (CRC). As an important pathway of cellular energy metabolism, fatty acid metabolism plays an important role in cellular energy supply and oxidation balance, but presently, our understanding of the exact role of fatty acid metabolism in CRC is limited. Currently, no lipid metabolism therapy is available for the treatment of CRC. The establishment of a lipidmetabolism model regulated by oncogenes/tumor suppressor genes and associated with the clinical characteristics of CRC is necessary to further understand the mechanism of fatty acid metabolism in CRC. In this study, through multi-data combined with bioinformatic analysis and basic experiments, we introduced a tumor suppressor gene, EPHX2, which is rarely reported in CRC, and confirmed that its inhibitory effect on CRC is related to fatty acid degradation.

Keywords